You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
東陽光藥(01558.HK)上半年盈轉虧至5.07億元
格隆匯 08-28 01:22

格隆匯8月28日丨東陽光藥(01558.HK)公佈,截至2021年6月30日止6個月,營業額為人民幣2.02億元,同比減少90.3%;毛利為人民幣1.01億元,同比減少94.2%;税息、折舊及攤銷前虧損為人民幣3.54億元,去年同期盈利人民幣9.30億元下;歸屬於公司權益持有人的虧損及全面虧損總額(不考慮可轉換債券影響)為人民幣3.46億元,去年同期盈利人民幣6.96億元;歸屬於公司權益持有人的虧損及全面虧損總額(考慮可轉換債券影響)為人民幣5.07億元,去年同期盈利人民幣6.18億元。每股基本及攤薄虧損分別為人民幣0.58元及人民幣0.31元。

公吿稱,營收減少主要由於2020年新冠病毒疫情初期疊加流感高峯季,終端醫院機構對公司核心產品可威備貨需求較高,因此公司在疫情初期有較多可威發貨;2020年新冠病毒疫情爆發後,國內疫情防控嚴峻,導致終端醫療機構患者人流急速下降,終端處方量隨之下降,且由於疫情期間,人們防護意識加強、社交頻率驟降等原因,導致可威渠道庫存消耗速度較低;由於疫情前期可威發貨數量較多,以及疫情爆發後,終端可威處方量需求降低,導致可威於去年至今始終處於去庫存階段,故導致公司2021年上半年業績相較於2020年上半年有較大幅度下滑。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account